股本结构
单位：万股
| 公告日期 | 2026-08-05 | 2026-08-05 | 2026-05-13 | 2026-04-29 | 2026-04-29 | 2026-05-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 936.15 | 936.14 | 934.82 | 934.82 | 959.82 | 959.77 |
| 普通股本 | 936.15 | 936.14 | 934.82 | 934.82 | 959.82 | 959.77 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-03 | 2026-06-30 | 2026-05-11 | 2026-04-27 | 2026-04-21 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-05 | 936.15 | 未披露 | 定期报告 | 2026-08-03 |
| 2026-08-05 | 936.14 | 未披露 |
更多>>
From March 31, 2026 to June 30, 2026
Exchange of common stock for pre-funded warrant, net of issuance costs of $22
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Purchase of common stock under Employee Stock Purchase Plan
Shares withheld for taxes
|
2026-06-30 |
| 2026-05-13 | 934.82 | 未披露 | 定期报告 | 2026-05-11 |
| 2026-04-29 | 934.82 | 未披露 | 定期报告 | 2026-04-27 |
| 2026-04-29 | 959.82 | 未披露 | 定期报告 | 2026-04-21 |
| 2026-05-13 | 959.77 | 未披露 |
更多>>
From December 31,2025 to March 31,2026
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2026-03-31 |
| 2026-03-12 | 959.64 | 未披露 | 定期报告 | 2026-03-10 |
| 2026-03-12 | 958.68 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $5.2 million
Purchase of common stock under Employee Stock Purchase Plan
|
2025-12-31 |
| 2025-12-29 | 960.00 | 未披露 |
更多>>
a one-for-16 reverse stock split of Adicet's common stock
|
2025-12-30 |
| 2025-12-29 | 15330.00 | 未披露 | 定期报告 | 2025-12-29 |
| 2025-11-17 | 15325.56 | 未披露 | 定期报告 | 2025-11-14 |
| 2025-11-05 | 15325.56 | 未披露 | 定期报告 | 2025-11-03 |
| 2025-10-07 | 15325.48 | 未披露 |
更多>>
Common Stock offered 70,001,000 shares by the company
|
2025-10-08 |
| 2025-11-05 | 8325.38 | 未披露 |
更多>>
From June 30,2025 to September 30,2025
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2025-09-30 |
| 2025-08-07 | 8325.38 | 未披露 | 定期报告 | 2025-08-05 |
| 2025-08-07 | 8325.25 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock upon vesting of restricted stock
Purchase of common stock under Employee Stock Purchase Plan
|
2025-06-30 |
| 2025-05-06 | 8270.96 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2025-03-31 |
| 2025-03-06 | 8268.58 | 未披露 | 定期报告 | 2025-03-03 |
| 2025-03-06 | 8256.92 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $6.3 million
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $0.6 million
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
|
2024-12-31 |
| 2024-08-13 | 8240.10 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock upon vesting of restricted stock
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
|
2024-06-30 |
| 2024-05-14 | 8217.35 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-05-14 | 8216.95 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $0.6 million
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $6.3 million
|
2024-03-31 |
| 2024-03-19 | 8215.40 | 未披露 | 定期报告 | 2024-03-14 |
| 2024-01-24 | 7672.55 | 未披露 |
更多>>
Common stock offered 27,054,667 shares by the company
|
2024-01-25 |
| 2024-01-22 | 4967.08 | 未披露 | 定期报告 | 2024-01-19 |
| 2024-03-19 | 4327.04 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2023-12-31 |
| 2023-11-08 | 4316.45 | 未披露 | 定期报告 | 2023-11-06 |
| 2023-11-08 | 4310.79 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2023-09-30 |
| 2023-08-09 | 4306.62 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
|
2023-06-30 |
| 2023-05-09 | 4295.76 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-09 | 4295.74 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
|
2023-03-31 |
| 2023-03-15 | 4295.50 | 未披露 | 定期报告 | 2023-03-10 |
| 2023-03-15 | 4295.48 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million
Issuance of common stock upon exercise of warrants
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
|
2022-12-31 |
| 2022-11-08 | 4285.13 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-08 | 4278.77 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of 1,600,000 million
|
2022-09-30 |
| 2022-08-10 | 4003.08 | 未披露 | 定期报告 | 2022-08-05 |
| 2022-08-10 | 4002.08 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of warrants
Purchase of common stock under ESPP
|
2022-06-30 |
| 2022-05-12 | 4000.44 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-04-21 | 4000.40 | 未披露 | 定期报告 | 2022-04-07 |
| 2022-04-21 | 3998.84 | 未披露 | 定期报告 | 2022-04-05 |
| 2022-05-12 | 3988.58 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
|
2022-03-31 |
| 2022-03-15 | 3987.71 | 未披露 | 定期报告 | 2022-03-10 |
| 2022-03-15 | 3973.69 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock upon exercise of stock options
Issuance of common stock related to financing, net of issuance costs of $823,940
Issuance of common stock for cashless exercise of warrants
Issuance of common stock resulting from Employee Stock Purchase Plan
|
2021-12-31 |
| 2021-12-10 | 3820.51 | 未披露 |
更多>>
1.Common stock offered by company 6,250,000 shares.
2.All information in this prospectus supplement related to the number of shares of common stock to be outstanding immediately after this offering is based on 31,955,050 shares outstanding as of September 30, 2021.
|
2021-12-10 |
| 2021-12-07 | 3195.57 | 未披露 | 定期报告 | 2021-11-30 |
| 2021-11-10 | 3195.55 | 未披露 | 定期报告 | 2021-11-09 |
| 2021-11-10 | 3195.51 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock upon exercise of stock options
|
2021-09-30 |
| 2021-08-12 | 3184.23 | 未披露 | 定期报告 | 2021-08-10 |
| 2021-08-12 | 3184.20 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock upon exercise of stock options
|
2021-06-30 |
| 2021-05-17 | 3181.35 | 未披露 | 定期报告 | 2021-05-12 |
| 2021-05-17 | 3180.24 | 未披露 |
更多>>
from December 31, 2020 to March 31, 2021
Issuance of common stock upon exercise of stock options
Issuance of common stock related to financing
Exercise of warrant
|
2021-03-31 |
| 2021-03-18 | 3180.04 | 未披露 | 定期报告 | 2021-03-16 |
| 2021-03-12 | 3178.03 | 未披露 | 定期报告 | 2021-03-10 |
| 2021-03-18 | 3158.13 | 未披露 | 定期报告 | 2021-03-01 |
| 2021-02-12 | 2997.42 | 未披露 |
更多>>
1.Common stock offered by the company 9,230,770 shares.
2.All information in this prospectus supplement related to the number of shares of common stock to be outstanding immediately after this offering and the concurrent private placement is based on 19,589,637 shares outstanding as of September 30, 2020.
|
2021-02-12 |
| 2021-02-10 | 1968.17 | 未披露 | 定期报告 | 2021-01-31 |
| 2021-03-12 | 1967.72 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock upon exercise of stock options
Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger
Exchange of common stock in connection with the Merger
Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger
|
2020-12-31 |
| 2020-12-01 | 1962.92 | 未披露 | 定期报告 | 2020-11-30 |
| 2020-11-05 | 1960.06 | 未披露 | 定期报告 | 2020-11-03 |
| 2020-11-05 | 1958.96 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger
Exchange of common stock in connection with the Merger
|
2020-09-30 |
| 2020-09-16 | 1958.98 | 未披露 |
更多>>
On September 15, 2020, the Company completed the Merger pursuant to the Merger Agreement. In connection with the Merger, and immediately prior to the Effective Time, the Company effected a reverse stock split of the Company Common Stock at a ratio of 1-for-7 (the “Reverse Stock Split”). Also, in connection with the Merger, the Company changed its name from “resTORbio, Inc.” to “Adicet Bio, Inc.” (the “Name Change”), Adicet changed its name from “Adicet Bio, Inc.” to “Adicet Therapeutics, Inc.” and the business conducted by the Company became primarily the business conducted by Adicet, which is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.
|
2020-09-17 |
| 2020-07-29 | 3645.39 | 未披露 | 定期报告 | 2020-07-22 |
| 2020-06-23 | 3644.69 | 未披露 |
更多>>
From March 31, 2020 to June 16, 2020
Vesting of restricted stock units, net of shares withheld for taxes
|
2020-06-16 |
| 2020-05-07 | 3644.58 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Vesting of restricted stock units, net of shares withheld for taxes
|
2020-03-31 |
| 2020-03-12 | 3644.58 | 未披露 | 定期报告 | 2020-03-11 |
| 2020-03-12 | 3644.47 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $3,683
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $285
Vesting of restricted stock
Vesting of restricted stock units, net of shares withheld for taxes
Exercise of stock options
|
2019-12-31 |
| 2019-11-05 | 3644.36 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $221
Vesting of restricted stock units, net of shares withheld for taxes
|
2019-09-30 |
| 2019-08-14 | 3622.17 | 未披露 | 定期报告 | 2019-08-13 |
| 2019-08-14 | 3581.74 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $228
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $64
Vesting of restricted shares
Vesting of restricted stock units
Exercise of stock options
|
2019-06-30 |
| 2019-05-15 | 3574.33 | 未披露 | 定期报告 | 2019-05-14 |
| 2019-05-15 | 3525.53 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $3,455
Vesting of restricted shares
|
2019-03-31 |
| 2019-03-18 | 2805.53 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Conversion of convertible preferred stock into common stock upon the closing of initial public offering
|
2018-12-31 |
| 2018-11-13 | 2805.53 | 未披露 | 定期报告 | 2018-11-12 |
| 2018-08-09 | 2804.83 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-10 | 2804.63 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-29 | 2804.63 | 未披露 | 定期报告 | 2018-03-23 |
| 2018-01-29 | 2719.63 | 未披露 |
更多>>
1.Common stock offered 5,666,667 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 5,659,089 shares of our common stock outstanding as of January 16, 2018
3.a 1-for-1.2804 reverse split of our common stock effected on January 12, 2018
|
2018-01-26 |
| 2018-03-29 | 565.91 | 2032.07 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series A redeemable convertible preferred stock, net of tranche liability
Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $54
Vesting of restricted shares
|
2017-12-31 |
| 2018-01-16 | 565.91 | 776.40 | 定期报告 | 2017-09-30 |
| 2018-01-16 | 377.27 | 未披露 | 定期报告 | 2016-12-31 |
From March 31, 2026 to June 30, 2026
Exchange of common stock for pre-funded warrant, net of issuance costs of $22
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Purchase of common stock under Employee Stock Purchase Plan
Shares withheld for taxes
From December 31,2025 to March 31,2026
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From December 31, 2024 to December 31, 2025
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $5.2 million
Purchase of common stock under Employee Stock Purchase Plan
a one-for-16 reverse stock split of Adicet's common stock
Common Stock offered 70,001,000 shares by the company
From June 30,2025 to September 30,2025
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From March 31, 2025 to June 30, 2025
Issuance of common stock upon vesting of restricted stock
Purchase of common stock under Employee Stock Purchase Plan
From December 31, 2024 to March 31, 2025
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From December 31, 2023 to December 31, 2024
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $6.3 million
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $0.6 million
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
From March 31, 2024 to June 30, 2024
Issuance of common stock upon vesting of restricted stock
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
From December 31, 2023 to March 31, 2024
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $0.6 million
Issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs of $6.3 million
Common stock offered 27,054,667 shares by the company
From December 31, 2022 to December 31, 2023
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From June 30, 2023 to September 30, 2023
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From March 31, 2023 to June 30, 2023
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
From December 31, 2022 to March 31, 2023
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of $1.6 million
Issuance of common stock upon exercise of warrants
Shares withheld for taxes
Issuance of common stock upon exercise of stock options
Purchase of common stock under Employee Stock Purchase Plan
Issuance of common stock upon vesting of restricted stock
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
Issuance of common stock pursuant to at-the-market offering, net of issuance costs of 1,600,000 million
From March 31, 2022 to June 30, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon exercise of warrants
Purchase of common stock under ESPP
From December 31, 2021 to March 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock
Shares withheld for taxes
From December 31, 2020 to December 31, 2021
Issuance of common stock upon exercise of stock options
Issuance of common stock related to financing, net of issuance costs of $823,940
Issuance of common stock for cashless exercise of warrants
Issuance of common stock resulting from Employee Stock Purchase Plan
1.Common stock offered by company 6,250,000 shares.
2.All information in this prospectus supplement related to the number of shares of common stock to be outstanding immediately after this offering is based on 31,955,050 shares outstanding as of September 30, 2021.
From June 30, 2021 to September 30, 2021
Issuance of common stock upon exercise of stock options
From March 31, 2021 to June 30, 2021
Issuance of common stock upon exercise of stock options
from December 31, 2020 to March 31, 2021
Issuance of common stock upon exercise of stock options
Issuance of common stock related to financing
Exercise of warrant
1.Common stock offered by the company 9,230,770 shares.
2.All information in this prospectus supplement related to the number of shares of common stock to be outstanding immediately after this offering and the concurrent private placement is based on 19,589,637 shares outstanding as of September 30, 2020.
From December 31, 2019 to December 31, 2020
Issuance of common stock upon exercise of stock options
Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger
Exchange of common stock in connection with the Merger
Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger
From June 30, 2020 to September 30, 2020
Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger
Exchange of common stock in connection with the Merger
On September 15, 2020, the Company completed the Merger pursuant to the Merger Agreement. In connection with the Merger, and immediately prior to the Effective Time, the Company effected a reverse stock split of the Company Common Stock at a ratio of 1-for-7 (the “Reverse Stock Split”). Also, in connection with the Merger, the Company changed its name from “resTORbio, Inc.” to “Adicet Bio, Inc.” (the “Name Change”), Adicet changed its name from “Adicet Bio, Inc.” to “Adicet Therapeutics, Inc.” and the business conducted by the Company became primarily the business conducted by Adicet, which is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.
From March 31, 2020 to June 16, 2020
Vesting of restricted stock units, net of shares withheld for taxes
From December 31, 2019 to March 31, 2020
Vesting of restricted stock units, net of shares withheld for taxes
From December 31, 2018 to December 31, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $3,683
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $285
Vesting of restricted stock
Vesting of restricted stock units, net of shares withheld for taxes
Exercise of stock options
from June 30, 2019 to September 30, 2019
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $221
Vesting of restricted stock units, net of shares withheld for taxes
from March 31, 2019 to June 30, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $228
Issuance of common stock pursuant to the at-the-market offering, net of issuance costs of $64
Vesting of restricted shares
Vesting of restricted stock units
Exercise of stock options
from December 31, 2018 to March 31, 2019
Issuance of common stock upon closing of public offering, net of issuance costs of $3,455
Vesting of restricted shares
from December 31, 2017 to December 31, 2018
Conversion of convertible preferred stock into common stock upon the closing of initial public offering
1.Common stock offered 5,666,667 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 5,659,089 shares of our common stock outstanding as of January 16, 2018
3.a 1-for-1.2804 reverse split of our common stock effected on January 12, 2018
from December 31, 2016 to December 31, 2017
Issuance of Series A redeemable convertible preferred stock, net of tranche liability
Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $54
Vesting of restricted shares